<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518658</url>
  </required_header>
  <id_info>
    <org_study_id>500</org_study_id>
    <nct_id>NCT03518658</nct_id>
  </id_info>
  <brief_title>BlueSync Field Evaluation</brief_title>
  <official_title>BlueSync Field Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this field evaluation is to collect and evaluate information related to
      CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the
      health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal is to learn how many CareLink quarterly scheduled transmissions are
      completed within a prescribed time period to assess CareLink scheduled transmission
      compliance. The evaluation will also assess adoption to remote monitoring, patient perceived
      benefit of BlueSync™ (how patients interact with the smart device application) and health
      care provider perception of the value of BlueSync™ and satisfaction with BlueSync™ (benefits
      experienced by clinicians that use BlueSync™).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carelink compliance to transmission schedule</measure>
    <time_frame>Change in scheduled transmissions between 3 and 12 months after enrollment</time_frame>
    <description>CareLink transmission compliance (adherence to scheduled transmission), the primary objective is to compare the proportions of the CareLink quarterly scheduled transmissions that are completed within the prescribed window during the 12-month follow-up after the baseline visit in the CareLink Database between the evaluation patients who use the MyCareLink Heart™ (MCL) app and patients with low power devices and CareLink monitors 2490 (excluding wireless model 2490C).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute CareLink transmission compliance</measure>
    <time_frame>Two scheduled transmissions at 2 weeks and 4 weeks after enrollment</time_frame>
    <description>Proportion of the CareLink bi-weekly scheduled transmissions that are completed within the prescribed window during the 1-month follow-up after the baseline visit in the CareLink Database via the MCL Heart™ app.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>Evaluation Group</arm_group_label>
    <description>Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation Group</intervention_name>
    <description>Patient receiving exposure to the MyCareLink Heart App during device pairing</description>
    <arm_group_label>Evaluation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C)</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at hospitals and clinics specializing in the implant and followup of pacemakers
        and CRT-P devices using remote monitoring
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient will be/has been implanted with an Azure™ or Percepta™, Serena™, Solara™ CRT-P
             device compatible with BlueSync™ (both new and replacement devices are allowed)

          -  Patient must own a smart device (Smartphone or tablet) that meets system requirements
             and be willing to use during evaluation period

          -  Patient must be able to complete the required 12-month follow-up after enrollment

          -  Patients must be of legal age according to local law

        Exclusion Criteria:

          -  Patient unwilling to complete required surveys during 12-month evaluation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaldoun Trajki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keith Holloman, BA</last_name>
    <phone>7635261545</phone>
    <email>keith.holloman@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Carrithers, PH.D</last_name>
    <phone>7635262830</phone>
    <email>john.a.carrithers@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto clinico Città Studi</name>
      <address>
        <city>Milano</city>
        <zip>20131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augello, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore</name>
      <address>
        <city>Negrar</city>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulo Molon, MD</last_name>
      <email>giulio.molon@sacrocuore.it</email>
    </contact>
    <investigator>
      <last_name>Molon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sandwell and West Birmingham Hospitals</name>
      <address>
        <city>Birmingham</city>
        <zip>B71 4HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussien Hado, MD</last_name>
      <email>h.hado@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M139WC</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Zaidi, MD</last_name>
      <phone>7970191266</phone>
      <email>amir.zaidi@cmft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton</name>
      <address>
        <city>Southampton</city>
        <zip>SO166YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Roberts, MD</last_name>
      <email>Paul.Roberts@uhs.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>remote monitoring</keyword>
  <keyword>transmission compliance</keyword>
  <keyword>patient engagement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are not plans to share IPD with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

